INVITATION
LEARNING OBJECTIVES
1Empower HCPs with key strategies to treat their resistant hypertension patients to target2Discuss the implications.of earlier introduction of single-pill combination in reducing the incidence of resistant hypertension
3Understand how longer-.acting diuretics 3 differ from hydrochlorothiazide in blood pressure and CV outcomes
In May 2017, we will be introducing a series of live thought-provoking online forums to discuss the most common condition for which patients visit your of ce: hypertension. We kick off our first of this series with:
APPROACHING RESISTANT HYPERTENSION IN LIGHT
OF THE NEW 2017 HYPERTENSION CANADA GUIDELINES
We have built into this program a mix of clinical evidence, practical tips.and time for participation that we hope will contribute to a great session.
REGISTER NOWWe hope you will participate in what we consider to be a great opportunity to increase our.collective engagement in hypertension and look forward to speaking with you shortly.
This program is sponsored by Valeant Canada and Ilanga Pharma